Engagement of patients with advanced cancer (EPAC) randomized clinical trial: Long-term effects on survival and healthcare use.

Authors

null

Manali I. Patel

Stanford University - School of Medicine, Palo Alto, CA

Manali I. Patel, Madhuri Agrawal, Douglas W. Blayney, Steven M Asch, M. Kate Bundorf, Arnold Milstein

Organizations

Stanford University - School of Medicine, Palo Alto, CA, Medical Services, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, Stanford Cancer Institute, Stanford, CA, Department of Medicine, Primary Care, and Population Health, Stanford University, Stanford, CA, Duke University, Durham, NC, Stanford Clinical Excellence Research Center, Stanford, CA

Research Funding

U.S. National Institutes of Health
U.S. National Institutes of Health, VA

Background: The Engagement of Patients with Advanced Cancer (EPAC) randomized Veterans with newly diagnosed stage 3 or 4 cancer or recurrent disease to usual care (control) or usual care with 6-month community health worker (CHW) support (intervention) to engage Veterans in end-of-life (EOL) goals of care discussions. At 6- and 15-months follow-up, the intervention tripled goals of care documentation (primary), doubled hospice (secondary), and reduced end-of-life (EOL) acute care use (secondary) and total costs (secondary). This post-hoc analysis after 10 years from study initiation evaluates effects on overall survival (OS) and EOL healthcare use and costs. Methods: We abstracted dates of death, emergency department (ED), hospitalization, palliative care (PC), hospice use, and costs within and outside Veterans Affairs (VA) using electronic health record and claims before data cut-off on February 1, 2023 for all EPAC participants. We compared OS using Kaplan Meier and log-rank, risk of death using Cox-proportional hazard models, ED, hospitalization, PC, hospice use and costs in the last 30 days of life using Logistic Regression, and incidence rate ratios of ED and hospitalizations using Poisson regression. Results: Among 213 participants, there were no imbalances in demographic or clinical characteristics. 165 (77.4%) were White, 211 (99%) males, 80 (37.6%) had lung cancer, and 118 (55.3%) had stage 4 disease. Median follow-up was 298 days (range 12-3438). Intervention group participants had greater OS (log rank p=0.03), 25% reduction in risk of death, lower acute care use, greater PC and hospice, and lower total costs (p<0.001) than control group participants. Conclusions: The CHW-led intervention significantly improved OS and maintained robust effects on EOL healthcare use and costs. Results support integration of CHWs into care to improve clinical outcomes. Clinical trial information: NCT02966509.

TotalControl
Group
Intervention GroupHazard Ratio (HR), Odds Ratio (OR), Incidence Rate Ratio (IRR) (95% Confidence Interval)
Death – no. (%)188/213 (88.3)100 (92.5)88 (83.8)HR 0.75 (0.56-0.98)
ED Use in last 30 days of life – no. (%)67/188 (35.6)47/100 (47.0)20/88 (22.7)OR 0.33 (0.18-0.63)
ED Visits in last 30 days of life – mean +/- Standard Deviation (SD)0.53 +/- 0.860.79 +/- 1.020.25 +/- 0.48IRR 0.31 (0.19-0.50)
Hospitalization Use in last 30 days of life – no. (%)63/188 (33.5)46/100 (46.0)17/88 (19.3)OR 0.28 (0.15-0.54)
Hospitalizations in last 30 days of life – mean +/- SD0.48 +/- 0.800.71 +/- 0.950.22 +/- 0.47IRR 0.30 (0.18-0.50)
Palliative care – no. (%)79/188 (42.0)35/100 (35.0)44/88 (50.0)OR 1.86 (1.03-3.33)
Hospice – no. (%)117/188 (62.2)53/100 (53.0)64/88 (72.7)OR 2.36 (1.28-4.36)
Total Costs USD– median (range)7,047 (29-223,053)18,520 (43-223,053)1,636 (29-111,095)---------------------

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Quality Care Symposium

Session Type

Oral Abstract Session

Session Title

Oral Abstract Session B

Track

Health Care Access, Equity, and Disparities,Palliative and Supportive Care,Survivorship

Sub Track

Interventions and Policies to Optimize Health Equity

Clinical Trial Registration Number

NCT02966509

Citation

JCO Oncol Pract 19, 2023 (suppl 11; abstr 76)

DOI

10.1200/OP.2023.19.11_suppl.76

Abstract #

76

Abstract Disclosures

Similar Abstracts

First Author: Anshu Hemrajani

First Author: Kah Poh Loh

Abstract

2023 ASCO Annual Meeting

Mortality among oncology patients with multiple unplanned hospital admissions.

First Author: Thomas J Roberts

Abstract

2018 Palliative and Supportive Care in Oncology Symposium

Examining the intersection of palliative care, hospice, and concurrent care in Veterans Affairs (VA).

First Author: Kathleen Elizabeth Bickel